Swiss Labs Modifying Arthri-Zen Claims After ERSP Review

NEW YORKAfter a review of advertising for the Arthri-Zen Relief dietary supplement by the Electronic Retailing Self-Regulation Program (ERSP), Swiss Labs Inc. agreed to modify certain claims but will continue with others that were found to have reliable support. The review included evidence from a randomized, double blind, placebo-controlled clinical trial on the Arthri-Zen Relief formulation.

ERSP determined the study provided support for claims about reducing joint and muscle discomfort, although the fact that it was a single study led to a recommendation that Swiss Labs discontinue mentions of clinical studies. Further, while the study found subjects experienced relief within four days, the claim about immediate relief could be considered misleading to consumer expectations; Swiss Labs agreed to modify the immediate relief claim.